Intech Investment Management LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Intech Investment Management LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 12,593 shares of the specialty pharmaceutical company’s stock, valued at approximately $751,000. Intech Investment Management LLC owned 0.06% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in ANI Pharmaceuticals during the second quarter worth approximately $65,000. Ridgewood Investments LLC purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $85,000. O Shaughnessy Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth about $218,000. XTX Topco Ltd purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $207,000. Finally, Profund Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $225,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANIP opened at $57.23 on Friday. The company has a market capitalization of $1.20 billion, a P/E ratio of -104.05 and a beta of 0.71. The company has a 50-day moving average of $58.26 and a 200-day moving average of $60.74. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same period in the previous year, the company earned $1.05 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 33,981 shares of company stock valued at $1,970,066. Corporate insiders own 12.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ANIP shares. Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright restated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.